CIK 0001870404 · <br>Emerging growth company
CERO THERAPEUTICS HOLDINGS, INC.
Sign in to watch- Tickers
- CERO CEROW
- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 871088814
- Phone
- 650-407-2376
- Business address
- 201 HASKINS WAY, SUITE 230, SOUTH SAN FRANCISCO, CA, 94080
- Former names
- CERO THERAPEUTICS HOLDINGS, INC., PHOENIX BIOTECH ACQUISITION CORP.
Securities
- CERO Common stock OTC
- CEROW Common stock OTC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-12-06 | YK Bioventures Opportunities GP I, LLC 10% owner | Sale | −1,236,874 | $0.12 | $148K | 21,383,909 |
| 2024-12-02 | Ehrlich Christopher B Chairman and CEO | Grant or award · Stock Option (Right to Buy) | +1,275,000 | 1,275,000 | ||
| 2024-12-02 | Rolfe Lindsey Director | Grant or award · Stock Option (Right to Buy) | +127,500 | 127,500 | ||
| 2024-12-02 | LAPORTE KATHLEEN Director | Grant or award · Stock Option (Right to Buy) | +127,500 | 127,500 | ||
| 2024-12-02 | Byrnes Michael Director | Grant or award · Stock Option (Right to Buy) | +127,500 | 127,500 | ||
| 2024-12-02 | ATWOOD BRIAN G Director | Grant or award · Stock Option (Right to Buy) | +254,000 | 254,000 | ||
| 2024-12-02 | Patel Shami Director | Grant or award · Stock Option (Right to Buy) | +127,500 | 127,500 | ||
| 2024-10-10 | YK Bioventures Opportunities GP I, LLC 10% owner | Sale | −3,250,000 | $0.10 | $325K | 22,620,783 |
| 2024-10-01 | KUCHARCHUK ANDREW ALBERT Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +500,000 | 500,000 | ||
| 2024-10-01 | Pierce Kristen Chief Development Officer | Grant or award · Stock Option (Right to Buy) | +200,000 | 200,000 | ||
| 2024-09-30 | Ehrlich Christopher B Interim Chairman and CEO | Returned to the company · Stock Option (Right to Buy) | −572,182 | 0 | ||
| 2024-09-30 | ATWOOD BRIAN G Director | Returned to the company · Stock Option (Right to Buy) | −13,857 | 0 | ||
| 2024-09-30 | ATWOOD BRIAN G Director | Returned to the company · Stock Option (Right to Buy) | −1,317,956 | 0 | ||
| 2024-09-25 | SLOAN STUART M 10% owner | Sale | −532,486 | $0.10 | $56K | 21,067,956 |
| 2024-09-25 | LAPORTE KATHLEEN Director | Option exercise | +965,997 | 965,997 | ||
| 2024-09-25 | LAPORTE KATHLEEN Director | Option exercise · Series A Convertible Preferred Stock | −50 | $1,000.00 | $50K | 0 |
| 2024-09-25 | Ehrlich Christopher B Interim Chairman and CEO | Option exercise | +5,312,983 | 5,791,808 | ||
| 2024-09-25 | Ehrlich Christopher B Interim Chairman and CEO | Option exercise · Series A Convertible Preferred Stock | −275 | $1,000.00 | $275K | 0 |
| 2024-09-25 | ATWOOD BRIAN G Director | Option exercise | +19,358,578 | 19,607,313 | ||
| 2024-09-25 | ATWOOD BRIAN G Director | Option exercise · Series A Convertible Preferred Stock | −1,002 | $1,000.00 | $1.0M | 0 |
Page 3 of 6 · 120 trades